Nanopharm-logo-with-signature-Pantone (1)
Close this search box.

10 Dec 2021

Propellant Aerosols & Transition to Low GWP pMDIs


This presentation provides a comprehensive overview of the evolution of Pressurised Metered Dose Inhalers (pMDIs) from their inception to the current focus on Low Global Warming Potential (GWP) propellants. It highlights the significant milestones in the journey of pMDIs, starting from the approval of the first pMDI, Medihaler Iso, to the current research on low GWP propellants. 

The presentation also discusses the key considerations for switching propellants, including propellant selection, container closure system material compatibility, formulation specificities, and dose selection. It provides valuable insights into the challenges and opportunities in the development of pMDIs with low GWP propellants. 

This presentation is a valuable resource for anyone interested in the development of pMDIs and the future of inhaler technology.

Related Posts


Nanopharm Announces Exclusive Collaboration With Fluidda To Accelerate Regulatory Pathway For OINDP Using SmartTrack

Crystal Lake, Illinois, September 22, 2022 – Nanopharm, an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products (OINDPs), today announced an exclusive collaboration with Fluidda, a leader in the field of Functional Respiratory Imaging. The companies will leverage their respective proprietary technology platforms to help accelerate U.S. Food & Drug Administration (FDA) approvals for orally inhaled generic products (OIDPs) via the alternative bioequivalence pathway. Nanopharm was acquired by Aptar (NYSE: ATR) in 2019, as part of the company’s strategy to expand its services offerings and partner with pharmaceutical companies earlier in the drug development process.

Read More »